Analyst Jill Wu of CMB International Securities maintained a Buy rating on Shanghai Henlius Biotech, Inc. Class H, boosting the price target to HK$97.75.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jill Wu’s rating is based on Shanghai Henlius Biotech’s robust financial performance and promising product pipeline. The company reported revenue growth in the first half of 2025, with drug sales meeting nearly half of the full-year forecast. Despite some competition affecting specific products, Henlius is expected to benefit from additional upfront payments through strategic partnerships with major pharmaceutical companies.
Furthermore, the company’s innovative biologics, particularly HLX43, show significant potential in treating various cancers, with promising trial results in NSCLC and other indications. Henlius is also advancing its global registration efforts for serplulimab, which has already received approvals in several regions. The company’s focus on developing early-stage assets and maintaining strong cash inflows from biosimilars supports its transition into an innovative biologics leader. These factors contribute to the Buy rating and the revised target price.
Wu covers the Healthcare sector, focusing on stocks such as Shanghai Henlius Biotech, Inc. Class H, BeOne Medicines, and CSPC Pharmaceutical Group. According to TipRanks, Wu has an average return of 45.1% and a 63.56% success rate on recommended stocks.